Forkhead domain mutations in FOXA1 drive prostate cancer progression.
作者信息
Gao Shuai, Chen Sujun, Han Dong, Barrett David, Han Wanting, Ahmed Musaddeque, Patalano Susan, Macoska Jill A, He Housheng Hansen, Cai Changmeng
机构信息
Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, 02125, USA.
Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
出版信息
Cell Res. 2019 Sep;29(9):770-772. doi: 10.1038/s41422-019-0203-2. Epub 2019 Jul 19.
Abstract
摘要
相似文献
1
Forkhead domain mutations in FOXA1 drive prostate cancer progression.FOXA1中的叉头结构域突变会推动前列腺癌进展。
Cell Res. 2019 Sep;29(9):770-772. doi: 10.1038/s41422-019-0203-2. Epub 2019 Jul 19.
2
Altered chromatin recruitment by FOXA1 mutations promotes androgen independence and prostate cancer progression.FOXA1突变导致的染色质募集改变促进雄激素非依赖性和前列腺癌进展。
Cell Res. 2019 Sep;29(9):773-775. doi: 10.1038/s41422-019-0204-1. Epub 2019 Jul 19.
3
Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.FoxA1 在前列腺癌转移中的雄激素受体非依赖性功能。
Cancer Res. 2013 Jun 15;73(12):3725-36. doi: 10.1158/0008-5472.CAN-12-3468. Epub 2013 Mar 28.
4
Pioneer of prostate cancer: past, present and the future of FOXA1.前列腺癌先驱：FOXA1 的过去、现在和未来。
Protein Cell. 2021 Jan;12(1):29-38. doi: 10.1007/s13238-020-00786-8. Epub 2020 Sep 18.
5
Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.晚期前列腺癌中 FOXA1 激活突变的不同结构类别。
Nature. 2019 Jul;571(7765):413-418. doi: 10.1038/s41586-019-1347-4. Epub 2019 Jun 26.
6
FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway.FOXA1 通过胰岛素样生长因子结合蛋白 3 途径促进前列腺癌的肿瘤进展。
PLoS One. 2012;7(8):e42456. doi: 10.1371/journal.pone.0042456. Epub 2012 Aug 3.
7
FoxA1 corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates the effect of MDV3100 (Enzalutamide™).FoxA1 会破坏比卡鲁胺的抗雄激素作用，但仅能轻微减弱 MDV3100（恩扎卢胺）的作用。
Mol Cell Endocrinol. 2013 Jan 5;365(1):95-107. doi: 10.1016/j.mce.2012.10.002. Epub 2012 Oct 11.
8
Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program.与FOXA1的协同作用和平衡决定了雄激素受体转录程序。
Nat Commun. 2014 May 30;5:3972. doi: 10.1038/ncomms4972.
9
Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer.FoxA1 在雄激素受体与染色质结合、雄激素信号传导和前列腺癌中的双重作用。
EMBO J. 2011 Sep 13;30(19):3962-76. doi: 10.1038/emboj.2011.328.
10
FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells.叉头框蛋白A1（FOXA1）调节EAF2对前列腺癌细胞中雄激素受体（AR）转录活性、细胞增殖和迁移的调控。
Prostate. 2015 Jun 15;75(9):976-87. doi: 10.1002/pros.22982. Epub 2015 Mar 23.
引用本文的文献
1
FOXA1-dependent NSUN2 facilitates the advancement of prostate cancer by preserving TRIM28 mRNA stability in a m5C-dependent manner.FOXA1 依赖的 NSUN2 通过以 m5C 依赖的方式维持 TRIM28 mRNA 的稳定性促进前列腺癌进展。
NPJ Precis Oncol. 2025 May 3;9(1):127. doi: 10.1038/s41698-025-00904-x.
2
FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer.FOXA2 重新为前列腺癌中的转录重编程和谱系可塑性构建了 AP-1。
Nat Commun. 2024 Jun 8;15(1):4914. doi: 10.1038/s41467-024-49234-9.
3
High clonal diversity and spatial genetic admixture in early prostate cancer and surrounding normal tissue.早期前列腺癌及周围正常组织中的高克隆多样性和空间遗传混合。
Nat Commun. 2024 Apr 24;15(1):3475. doi: 10.1038/s41467-024-47664-z.
4
FOXA1 and FOXA2: the regulatory mechanisms and therapeutic implications in cancer.叉头框蛋白A1（FOXA1）和叉头框蛋白A2（FOXA2）：癌症中的调控机制及治疗意义
Cell Death Discov. 2024 Apr 11;10(1):172. doi: 10.1038/s41420-024-01936-1.
5
Atypical inflammatory kinase IKBKE phosphorylates and inactivates FoxA1 to promote liver tumorigenesis.非典型炎性激酶 IKBKE 通过磷酸化和失活 FoxA1 促进肝肿瘤发生。
Sci Adv. 2024 Feb 9;10(6):eadk2285. doi: 10.1126/sciadv.adk2285. Epub 2024 Feb 7.
6
Unveiling the Molecular Landscape of Mutant Prostate Cancer: Insights and Prospects for Targeted Therapeutic Strategies.揭示突变型前列腺癌的分子图谱：靶向治疗策略的见解与展望。
Int J Mol Sci. 2023 Oct 31;24(21):15823. doi: 10.3390/ijms242115823.
7
SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1.SETD7 通过甲基化 FOXA1 作为转录抑制因子在前列腺癌中发挥作用。
Proc Natl Acad Sci U S A. 2023 Aug 15;120(33):e2220472120. doi: 10.1073/pnas.2220472120. Epub 2023 Aug 7.
8
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer.SYNCRIP 缺失会引发前列腺癌中的 APOBEC 驱动的突变、肿瘤异质性和 AR 靶向治疗耐药性。
Cancer Cell. 2023 Aug 14;41(8):1427-1449.e12. doi: 10.1016/j.ccell.2023.06.010. Epub 2023 Jul 20.
9
LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer.LSD1 抑制破坏去势抵抗性前列腺癌中超增强子驱动的致癌转录程序。
Cancer Res. 2023 May 15;83(10):1684-1698. doi: 10.1158/0008-5472.CAN-22-2433.
10
Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.原发前列腺癌中广泛的雄激素受体增强子异质性是转录多样性和转移潜能的基础。
Nat Commun. 2022 Nov 30;13(1):7367. doi: 10.1038/s41467-022-35135-2.
本文引用的文献
1
Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function Mutations.外显子组测序揭示非裔美国人前列腺癌中的功能丧失突变。
Cancer Discov. 2017 Sep;7(9):973-983. doi: 10.1158/2159-8290.CD-16-0960. Epub 2017 May 17.
2
The Molecular Taxonomy of Primary Prostate Cancer.原发性前列腺癌的分子分类学
Cell. 2015 Nov 5;163(4):1011-25. doi: 10.1016/j.cell.2015.10.025.
3
Integrative clinical genomics of advanced prostate cancer.晚期前列腺癌的整合临床基因组学
Cell. 2015 May 21;161(5):1215-1228. doi: 10.1016/j.cell.2015.05.001.
4
Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity.赖氨酸特异性去甲基化酶1作为雄激素受体转录活性的主要调节因子具有双重功能。
Cell Rep. 2014 Dec 11;9(5):1618-1627. doi: 10.1016/j.celrep.2014.11.008. Epub 2014 Dec 4.
5
Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.雄激素受体在去势抵抗性前列腺癌中的作用及新的靶向雄激素轴药物的耐药机制。
Oncogene. 2014 May 29;33(22):2815-25. doi: 10.1038/onc.2013.235. Epub 2013 Jun 10.
6
Modification of enhancer chromatin: what, how, and why?增强子染色质的修饰：是什么、如何修饰以及为什么要修饰？
Mol Cell. 2013 Mar 7;49(5):825-37. doi: 10.1016/j.molcel.2013.01.038.
7
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.外显子组测序鉴定前列腺癌中 SPOP、FOXA1 和 MED12 的高频突变。
Nat Genet. 2012 May 20;44(6):685-9. doi: 10.1038/ng.2279.
8
The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials.HGF/c-Met 信号通路在前列腺癌进展中的作用及 c-Met 抑制剂的临床试验研究。
Expert Opin Investig Drugs. 2011 Dec;20(12):1677-84. doi: 10.1517/13543784.2011.631523. Epub 2011 Oct 28.
9
FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription.叉头框蛋白A1（FoxA1）将表观遗传特征转化为增强子驱动的谱系特异性转录。
Cell. 2008 Mar 21;132(6):958-70. doi: 10.1016/j.cell.2008.01.018.
10
Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1.雌激素受体结合的全染色体图谱揭示了需要叉头蛋白FoxA1的长程调控。
Cell. 2005 Jul 15;122(1):33-43. doi: 10.1016/j.cell.2005.05.008.
Zotero 插件